Abnormal LTA or ATP secretion test results were identified in 58% of participants. In 84% of these, the patterns of response were consistent with defects in Gi receptor signalling, the thromboxane pathway and dense granule secretion. Participants with defects in signalling to Gq-coupled receptor agonists and to collagen were also identified. Targeted genotyping identified three participants with function disrupting mutations in the P2Y 12 ADP and thromboxane receptors. Our study illustrates that detailed phenotypic analysis using LTA and ATP secretion is a powerful tool for diagnosis of PFDs and enables subdivision at the level of platelet signaling pathways and in some cases to individual receptors. We further demonstrate that most PFD can be reliably diagnosed using a streamlined panel of key platelet agonists and specified concentrations suitable for testing in most clinical diagnostic laboratories.
Introduction
An adequate number of normally functioning platelets is essential in arresting haemorrhage from an injured blood vessel. Individuals with heritable platelet function disorders (PFDs) experience lifelong abnormal bleeding, typically at mucocutaneous sites or elsewhere after trauma or invasive procedures. This group of disorders is highly heterogeneous and can arise through defects in surface membrane receptors, signalling pathways, granule formation and secretion, cytoskeletal remodelling and expression of procoagulant activity 1, 2 . Diagnosis of the severe PFDs, Glanzmann's thrombasthaenia and Bernhard-Soulier syndrome, or syndromic PFDs, such as Hermansky Pudlak syndrome [HPS] ), is usually straightforward because of the characteristic clinical and laboratory features [3] [4] [5] [6] . On the other hand, poor standardization of platelet function tests and the lack of consensus surrounding minimal diagnostic criteria have hampered diagnosis of the remaining PFDs.
Light transmission aggregometry (LTA) is a long established method for the diagnosis of
PFDs. Responses to individual test agonists are typically classified as 'abnormal' if numerical parameters such as the level of maximal aggregation fall outside of the reference range of healthy donor controls or if there are qualitative differences between test and control aggregation curves 7, 8 . However, most PFDs are associated with abnormal responses to multiple agonists and it is unclear whether it is the number of 'abnormal responses' 8 or the specific patterns of 'abnormal response' 9 is the more powerful in the diagnosis of PFDs. The additional diagnostic value of ATP secretion in diagnosis of PFDs is not known.
We have previously defined reference intervals for LTA and dense granule secretion to three concentration of nine platelet agonists in a cohort of 20 healthy volunteers 9 . We now present data from the UK Genotyping and Phenotyping of Platelets (GAPP) study 10 that includes extended data on 70 healthy donor controls that validates our previous reference intervals 9 .
We also describe LTA and ATP secretion test results in a prospectively studied cohort of 111 patients with suspected PFDs registered at UK Haemophilia Comprehensive Care Centres. Glanzmann's thrombasthenia, Bernard-Soulier syndrome or Hermansky-Pudlak syndrome and those with platelet counts < 100 or > 450 x 10 9 / litre were excluded. Laboratory testing was deferred in participants exposed within two weeks to drugs known to affect platelet function. Information on the age and sex of the participants is given in the results section.
Materials and Methods

Selection of Participants
Healthy controls
Healthy donor volunteers aged 18 years or older were also included in this study. Controls were considered healthy if they did not have a history of bleeding symptoms, did not require long-term medical therapy and had refrained from drugs known to influence platelet function in the previous 2 weeks.
Ethics
This study was approved by the National Research Ethics Service Committee West
Midlands -Edgbaston (REC reference: 06/MRE07/36) and participants and controls gave written informed consent in accordance with the Declaration of Helsinki.
Platelet agonists and other reagents
ADP, adrenaline and U46619 were purchased from Sigma (Poole, UK 
Platelet preparation and measurement of aggregation and secretion
Blood from participants and a simultaneous healthy volunteer control were taken into sodium citrate (3.8%) and transported at ambient temperature (~20 o C) to the laboratory. In the majority of cases, blood was taken in the adjacent clinic but in some instances, samples from participants and healthy volunteers were transported over distances of up to 100 miles by courier to Birmingham, UK. We have demonstrated previously that the results in platelet rich plasma (PRP) from samples that have been transported in this way are indistinguishable to those from locally collected samples provided that the PRP is prepared at the site of testing 9 .
PRP was prepared by centrifugation at 200g for 10 min in a spin out rotor. Platelet aggregation and ATP secretion were measured in PRP using a dual Chronolog lumiaggregometer (Model 460 VS, Havertown, PA, USA). Autologous platelet-poor plasma (PPP) was used to set the aggregation scale prior to each study according to the manufacturer's instruction. All experimentation was performed within six hours of preparation of the PRP as previously published 9 . Priority was given to time sensitive agonists such as ADP and adrenaline which were always used first within four hours of blood collection 9, 11 . No adjustment was made to the platelet count as there was no significant difference in the aggregation curves to platelet agonists within the normal range of platelet count by comparison of the response to three platelet agonists in healthy volunteers at the two extreme ends of the normal range (Supplementary Figure 1) . This is consistent with previous reports [12] [13] [14] [15] .
Platelets from the participants and healthy volunteers were routinely exposed to ADP (3, 10, 30 and 100µM), adrenaline (10, 30 and 100µM), collagen (0.3, 1 and 3µg/ml), collagenrelated peptide (CRP: 1, 3 and 10µg/ml), PAR1 (10, 30 and 100µM) and PAR4 (100, 250 and 500µM) peptides, arachidonic acid (0.5, 1 and 1.5 mM), U46619 (1 and 3 mM) and ristocetin
(1, 1.25, 1.5 and 2 mg/ml). The responses to ADP and arachidonic acid were the first to be investigated as these are the major two feedback agonists and a significant number of participants were found to have defects in Gi-signalling or in the TxA 2 pathway 16 . This information was used to guide subsequent testing, notably in cases where the platelet volume was limiting.
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P2RY12 analysis
The P2RY12 coding sequence was amplified from genomic DNA and directly sequenced as described previously 17 .
Analysis of data
Aggregation responses at each agonist concentration were classified as abnormal by reference to a bank of local healthy volunteers 9 . ATP secretion was calculated by addition of a known concentration of ATP (4nmol) and normalised to a platelet count of 1 x 10 8 platelets /ml (Supplementary Figure 2) . Results are shown as mean + s.d. Statistical analysis was performed using a one tailed Student's t-test and Cohen's kappa statistics.
Results
The 111 
Major subgroups of PFDs
Comparing the pattern of response in the 64 participants with an identified defect in LTA or ATP secretion revealed that 54/64 (84%) could be assigned to three major diagnostic groups, namely with defects in Gi signaling, thromboxane A 2 pathway and granule secretion. The distribution of defects is in shown in Table 1 and the characteristic features of each subgroup are described below:
(i) Gi-like defect: 21 (32.8%) of the 64 index cases were diagnosed with a Gi-like defect.
This subgroup exhibited a defect in aggregation and secretion to the two Gi-coupled use only. (ii) Thromboxane A 2 pathway defect: 14 (21.9%) of the 64 index cases were diagnosed with a thromboxane pathway defect. This was characterized by a marked and selective defect in aggregation and secretion to arachidonic acid (1mM) as illustrated by the representative trace in Figure 2 . In three of the fourteen participants with this defect, a reduced response to the TxA 2 -mimetic U46619 was also seen indicating a defect at the level of the thromboxane receptor or its downstream signalling cascade. A normal aggregation response to U46619 is evidence for a defect in conversion of arachidonic acid to TxA 2 as the response to U46619 is insensitive to cyclooxygenase blockade 9, 18 . Aggregation and secretion to low concentrations of other platelet agonists was also reduced in this group, consistent with the positive feedback role of TxA 2 . For most agonists, full recovery was seen at higher concentrations (not shown), with the exceptions of ADP and adrenaline which exhibited a slowly decaying aggregation response and severely reduced or absent secondary wave, respectively (see Figure 2 ).
(iii) Dense granule-secretion defect: 19 (30%) of the 64 index cases were diagnosed with a dense granule secretion defect which could be due either to a defect in storage or secretion.
The level of secretion was dependent on the platelet count which was normalized to the response observed to PAR-1 ( Figure 3A) or PAR-4 peptides as outlined in the methods.
Participants were considered to have a significant defect in secretion when the response fell outside of the normal range determined in controls. A decrease in ATP secretion was observed to all agonists even though several, including PAR-1, PAR-4 and CRP, induced maximal, sustained aggregation at high concentrations. There was however a reduction in use only.
For personal at UNIVERSITY OF BIRMINGHAM on September 24, 2012. bloodjournal.hematologylibrary.org From aggregation to low concentrations of most platelet agonists, consistent with impairment of the feedback role of ADP and TxA 2. The response to a low concentration of collagen was notably markedly impaired as illustrated in the representative trace in Figure 3A . One agonist which showed a minimal change in its dose response curves for aggregation was ADP; this is consistent with our previous conclusion that secretion plays a minimal role in aggregation to the nucleotide 9 .
It is noteworthy that the PAR-1 peptide (100μM) elicited a limited degree of secretion of ATP in all index cases diagnosed with a secretion disorder ( Figure 3B ), with the exception of the index case (and also other related family members) with an HPS-8 mutation (homozygous) 19 . Secretion to the PAR-1 peptide (100μM) in participants diagnosed with a Gi or thromboxane pathway defect, as well as one participant with a homozygous P2Y 12 receptor mutation (see below) and two with a heterozygote TxA 2 receptor defect (see below and refer to 18 ) fell within the normal range ( Figure 3B ). These results demonstrate that the vast majority of participants diagnosed with a secretion disorder elicit a limited degree of dense granule secretion and that the maximal level of secretion to a high concentration of a PAR-1 peptide is unaffected by mutations in the P2Y 12 ADP or TxA 2 receptors.
Other, less common subgroups of PFDs
The comparison of the LTA and ATP secretion results in the remaining 10/64 (16%) of participants, along with additional tests, revealed several further subgroups as shown in Table   1 , namely defects in the GPVI signaling pathway, Gq receptor signaling and in the ADP and TxA 2 receptors (confirmed by gene sequencing). In two other participants, the pattern of defects could not assign to any of these groups and is described as complex to indicate the presence of defects in multiple pathways. These further subgroups are described below: Figure 4B) . ADP had no effect on cAMP formation by PGE 1 , whereas adrenaline induced a marked decrease in the second messenger (supplementary Figure 4) . This profile is indicative of a defect in the P2Y 12 ADP receptor. In confirmation of this, genomic DNA sequencing revealed that the participant was homozygous for a single base deletion at nucleotide position 36 of the P2RY12 gene. This mutation is predicted to cause a frameshift leading to introduction of a premature stop codon (c.36delG, p.Gly12fs) resulting in a failure to express the P2Y 12 receptor.
TxA 2 receptor mutations:
We have recently described a participant with a functiondisrupting heterozygous mutation in the TxA 2 receptor 18 . The defining features of this participant were a marked defect in aggregation and secretion to low concentrations of arachidonic acid and U46619. We have since identified a second participant who is heterozygous for a distinct mutation in the TxA 2 receptor which alters receptor trafficking (Nisar and Mundell in preparation). In both participants, the defect in aggregation and secretion is similar to that in participants with defective arachidonic acid metabolism described above, with the significant difference being the reduction in response to U46619.
GPVI pathway defect:
We have identified four index cases with a GPVI-like defect on the basis of a selective reduction in aggregation and secretion to the GPVI-specific agonist CRP, whereas the response to ADP, arachidonic acid and PAR1-and PAR4-specific peptides, were within the normal range (see Figure 5 and not shown). Aggregation and secretion to low concentrations of collagen were also reduced, although recovery was seen at higher concentrations as illustrated by the representative traces in Figure 5 . The weaker effect on collagen relative to CRP can be accounted for by the presence of a second collagen receptor on the platelet surface, integrin, α2β1, and by the marked dependency of the response of collagen on the feedback actions of ADP and TxA 2 . The snake venom toxin rhodocytin activates platelets through the C-type lectin receptor CLEC-2 which signals through a closely related signaling cascade to that of GPVI 20 . The demonstration of an impairment in aggregation to rhodocytin as illustrated in Figure 5 is indicative of a signalling defect downstream of GPVI or CLEC-2.
For personal at UNIVERSITY OF BIRMINGHAM on September 24, 2012. bloodjournal.hematologylibrary.org From Gq-like defect: One male index case, and his sister, from a non-consanguineous relationship, were observed to have a partial defect in aggregation and secretion to intermediate concentrations of agonists that signal through the heterotrimeric G proteins Gq and G 13 , namely PAR1-and PAR4-specific peptides and the TxA 2 analogue U46619 (Supplementary Figure 5) . In contrast, the responses to ADP and CRP were only marginally inhibited arguing against a general defect in platelet activation. This is further supported by the similar nature of the response to the phorbol ester PMA in the participant's platelets (Supplementary Figure   5) . Thus, the defect is putatively at the level of Gq or G 13 or their downstream signalling proteins.
Streamlined agonist panel testing
We next considered whether a reduced panel of LTA and ATP secretion tests would be sufficient to enable reliable diagnosis of PFD. Following review of the above results, we developed a streamlined panel of agonists and concentrations based on their ability to diagnose and discriminate the above subgroups of PFDs (Table 2) . We then undertook a comparison of the diagnosis of a PFD using this streamlined panel with the original agonist panel. These studies took into account the extent and time course of aggregation (noting whether it was transient or delayed) and the level of secretion of ATP, as the extent of maximal aggregation alone does not distinguish between the major three platelet function defect groups from controls ( Figure 6 ).
Two independent experts were blinded to previous diagnoses and reviewed data that would have been created using the streamlined agonist panel in 94 cases which were suitable for full analysis. Inter observer variation was minimal with an agreement of approximately 90% (kappa statistic 0.829, p value for significance <0.001). A mutually acceptable consensus was subsequently reached for the 10% of cases with a difference of opinion. The diagnoses from this process were then compared to the previous historical diagnoses using the expanded agonist list (Table 3 ). There was a significant level of agreement with a kappa statistic of 0.721 (p value for significance < 0.001). In addition, the sensitivity (87%), specificity (86%), negative predictive value (84%) and positive predictive value (88%) provided further verification of the streamlined agonist panel as shown in Table 3 .
Discussion
The most widely used test for platelet function is LTA which monitors the increase in light transmission through a suspension of platelets as aggregation proceeds. Among the advantages of this test is its relative simplicity, the ability to monitor responses to individual agonists over time and (in our experience) its reproducibility at the level of each donor.
Furthermore, it can be combined with real-time monitoring of ATP secretion in a lumiaggregometer by addition of the Luciferin-Luciferase reagent. The drawbacks of this method include the time taken to perform the assays and the fact that many investigators consider it to be operator-dependent and to give inconsistent results. The interpretation of aggregation traces is also complex due to the feedback effects of redundant platelet activation pathways, although this applies to all tests of platelet function. Several of these limitations can be minimised by standardisation of the aggregation and secretion assays as performed in this study. A similar standardisation of LTA was also used in a recent study of 229 participants to detect participants with platelet dysfunction 8 .
Defining the platelet phenotype through the analysis of aggregation and secretion to nine platelet agonists, alongside other functional tests, provides important information on the defective pathway(s) and in some cases the defective protein allowing targeted genetic analysis. It is not practical for hospital laboratories to follow this procedure however because of the time taken for the analysis and the relatively low numbers of participants that are referred to each centre. Nevertheless, a limited analysis of platelet aggregation using one or two concentrations of the 'standard' platelet agonists (ADP, adrenaline, AA, collagen and ristocetin) is extremely valuable in aiding diagnosis 8 .
In the present study, we have validated the use of a streamlined panel of six platelet agonists (see Table 3 ) by comparing the diagnoses made with the extended agonist panel. This 
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The majority of participants with an identified defect in platelet function (~80%) were assigned to one of three groups characterized by defects in Gi-signalling, thromboxane formation and dense granule secretion. This serves to emphasise the importance of these three pathways in supporting platelet activation during haemostasis. In the vast majority of these cases, the causative gene mutation(s) are not known and the value of the subgrouping is to enable further functional studies and targeted gene sequencing / gene interrogation.
The relatively small number of participants with defects in the Gq-pathway is perhaps surprising given the importance of this pathway in platelet activation. This may however reflect the fact that several platelet receptors signal through Gq-mediated pathways, namely PAR1, PAR4, P2Y 12 and TxA 2 receptors, thereby reducing the impact of a partial defect.
Alternatively, a mutation in this pathway could cause a more severe phenotype in other tissues that could be lethal in utero. The small number of participants with defects in the GPVI pathway is consistent with the relatively mild nature of bleeding associated with defects in the collagen receptor The phenotyping of platelets has been used to direct genotyping and has led to the identification of participants with a homozygous defect in the P2Y 12 ADP receptor gene (this study) and two heterozygous mutations in the TxA 2 receptor, one of which has been previously reported 18 . The homozygous P2Y 12 ADP receptor gene mutation reported in this study is the 10 th mutation to be reported in the nucleotide receptor 10 . A third heterozygous use only.
For personal at UNIVERSITY OF BIRMINGHAM on September 24, 2012. bloodjournal.hematologylibrary.org From mutation in the TxA 2 receptor has also recently been reported 22 . The only other reported mutation in the thromboxane receptor, Arg60Leu 23 , may be a rare SNP as there is no clear defect in function of the receptor in cell lines studies 24, 25 . We have not identified participants with mutations in the PAR1 and PAR4 thrombin receptors or the collagen receptor GPVI.
There are no reported participants with mutations in the PAR1 and PAR4 receptors, possibly because they are incompatible with life, and only two patients with mutations in GPVI have been reported 26, 27 . The small number of participants with mutations in platelet surface receptors suggests that receptor mutations account form a relatively small proportion of mutations that give rise to bleeding symptoms, with the majority being in intracellular signalling pathways or functional processes such as secretion or thromboxane formation.
Identifying the mutations that give rise to these function disorders requires a more high throughput approach offered by for example whole exome sequencing or a targeted second generation sequencing array 28 .
The present study represents a comprehensive investigation of participants with a clinically suspected platelet disorder alongside healthy volunteers. The participants have been grouped on the basis of the identified disorder, with the majority having defects in one of the major feedback pathways of platelet activation, namely Gi signalling, the thromboxane pathway and dense granule secretion. A handful of these participants have defects at the level of the ADP and thromboxane receptor but the majority have mutations downstream of receptor activation necessitating the use of second generation sequencing and targeted interrogation based on the functional results to establish the causative mutation(s). A streamlined platelet agonist list that could be performed in most clinical testing centres and a sequence of interpretation has been developed based on these results (Table 3) . Importantly, this interpretation takes into account the pattern but not the magnitude of the defect in aggregation, and whether secretion is also defective. Participants who exhibited a defect in platelet function were subdivided on the basis of their major platelet phenotype as described in the text. Participants identified with mutations in the P2Y 12 (present study) and TxA 2 receptors [10] and HPS-8 19 are identified by the presence of the square bracket. Aggregation and secretion in a participant (p) with a homozygous mutation in P2Y 12 which introduce an frame-shift early in the coding sequence (amino acid no. 12; see text).
Responses are shown alongside a control (c). The PRP platelet count in the control and participant were 4.1 x 10 8 /ml and 3.9 x 10 use only.
